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Abstract
Background  and  objectives: Adding  novel  adjunctive  drugs  like  gabapentinoids  to  multimodal
analgesic  regimen  might  be  reasonable  for  lessening  postoperative  pain  scores,  total  opioid  con-
sumption  and  side  effects  after  percutaneous  nephrolithotomy.  We  aimed  to  evaluate  the  effect
of  pregabalin  on  postoperative  pain  scores,  analgesic  consumption  and  renal  functions  expressed
by  creatinine  clearance  (CrCl)  and  blood  neutrophil  gelatinase-associated  lipocalin  (NGAL)  and
cystatin  C  (Cys  C)  levels  in  patients  undergoing  percutaneous  nephrolithotomy  (PCNL).
Methods:  60  patients  undergoing  elective  PCNL  were  enrolled  in  the  study.  Patients  were  ran-
domized  to  oral  single  dose  75  mg  pregabalin  group  and  a  control  group.  Visual  Analog  Scale  pain
scores  (VAS),  postoperative  intravenous  morphine  consumption  during  the  ﬁrst  24  postoperative
hours,  serum  NGAL,  Cys  C  levels  and  creatinine  clearance  (CrCl)  was  measured  preoperatively
and  post-operatively  at  2nd  and  24th  hour.
Results:  Postoperative  VAS  scores  were  signiﬁcantly  decreased  in  the  pregabalin  group  at  the
postoperative  30th  min,  1st,  and  2nd  hour  (p  =  0.002,  p  =  0.001  and  p  =  0.027,  respectively).
Postoperative mean  morphine  consumption  was  statistically  signiﬁcantly  decreased  for  all  time
intervals  in  the  pregabalin  group  (p  =  0.002,  p  =  0.001,  p  =  0.001,  p  =  0.001,  p  <  0.001,  respec-
tively). No  statistically  signiﬁcant  differences  were  found  between  the  two  groups  with  regard
ative  and  postoperative  2nd  and  24th  hour.  Postoperative  24th  hourto  CrCl,  or  Cys  C  at  preoper
NGAL  levels  were  signiﬁcantly  decreased  in  the  pregabalin  group  (p  =  0.027).
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Conclusions:  Oral  single-dose  preemptive  75  mg  pregabalin  was  effective  in  reducing  early  post-
operative pain  scores  and  total  analgesic  consumption  in  patients  undergoing  PCNL  without
leading  to  hemodynamic  instability  and  side  effects.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  
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Adic¸ão  de  75  mg  de  pregabalina  ao  regime  analgésico  reduz  escores  de  dor  e
consumo  de  opiáceos  em  adultos  após  nefrolitotomia  percutânea
Resumo
Justiﬁcativa  e  objetivos:  A  adic¸ão  de  novos  medicamentos  adjuvantes,  como  os  gabapenti-
noides, ao  regime  analgésico  multimodal  pode  ser  razoável  para  diminuir  os  escores  de  dor
no  pós-operatório,  o  consumo  total  de  opiáceos  e  os  efeitos  colaterais  após  nefrolitotomia  per-
cutânea.  Nosso  objetivo  foi  avaliar  durante  o  período  pós-operatório  o  efeito  de  pregabalina  nos
escores  de  dor,  consumo  de  analgésicos  e  func¸ões  renais  expressas  por  clearance  de  creatinina
(ClCr)  e  níveis  séricos  de  cistatina-C  (Cis-C)  e  lipocalina  associada  à  gelatinase  de  neutróﬁlos
(LAGN)  em  pacientes  submetidos  à  nefrolitotomia  percutânea  (NLPC).
Métodos: Sessenta  pacientes  submetidos  à  NLPC  eletiva  foram  incluídos  no  estudo.  Os  pacientes
foram randomizados  para  receber  pregabalina  oral  em  dose  única  de  75  mg  --  grupo  pregabalina
e grupo  controle.  Os  escores  de  dor  medidos  pela  Escala  Visual  Analógica  (EVA),  o  consumo  de
morﬁna  intravenosa  nas  primeiras  24  horas  de  pós-operatório,  LAGN  sérico,  níveis  de  Cis-C  e
clearance  de  creatinina  (ClCr)  foram  mensurados  no  pré-operátorio  e  na  segunda  e  24a  horas
de  pós-operatório.
Resultados:  Os  escores  EVA  no  pós-operatório  foram  signiﬁcativamente  menores  no  grupo  pre-
gabalina nos  tempos  de  30  min,  1  e  2  horas  (p  =  0,002,  p  =  0,001  e  p  =  0,027,  respectivamente).
A média  do  consumo  de  morﬁna  no  pós-operatório  foi  estatisticamente  signiﬁcante  menor  em
todos  os  intervalos  de  tempo  no  grupo  pregabalina  (p  =  0,002,  p  =  0,001,  p  =  0,001,  p  =  0,001,
p  <  0,001,  respectivamente).  Não  houve  diferenc¸a estatisticamente  signiﬁcante  entre  os  dois
grupos  em  relac¸ão  ao  ClCr  ou  Cis-C  no  pré-operatório  e  na  segunda  e  24a  horas  de  pós-
operatório. Os  níveis  de  LAGN  na  24a  hora  de  pós-operatório  foram  signiﬁcativamente  menores
no  grupo  pregabalina  (p  =  0,027).
Conclusões:  A  dose  única  de  75  mg  de  pregabalina  oral  administrada  precocemente  foi  eﬁcaz
na reduc¸ão  dos  escores  de  dor  no  pós-operatório  imediato  e  o  consumo  total  de  analgésicos  em
pacientes  submetidos  à  NLPC,  sem  causar  instabilidade  hemodinâmica  e  efeitos  colaterais.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  
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ercutaneous  nephrolithotomy  (PCNL)  is  a  common  surgical
ethod used  for  the  treatment  of  renal  calculi.1 Postop-
rative pain  due  to  dilatation  of  the  renal  capsule,  the
arenchymal tract,  and  peritubal  distressing  of  the  nephros-
omy tube2,3 is  one  of  the  complex  pain  conditions  in  urology.
ultimodal postoperative  pain  management  may  decrease
he incidence  of  complications,  the  requirement  for  hospi-
alization, and  decrease  recovery  times  and  health  costs.4
Opioids  have  an  important  role  in  postoperative  pain
anagement despite  important  side-effects5 that  might
ave signiﬁcant  impact  on  patient  recovery  after  surgery.6
hus,  multimodal  postoperative  pain  management  might
lso be  valuable  in  reducing  opioid-related  side-effects.7dding  novel  adjunctive  drugs  like  gabapentinoids  to  a  mul-
imodal analgesic  regimen,  which  has  been  shown  to  be
ffective in  postoperative  analgesia  in  different  procedures,
ight be  reasonable  for  lessening  postoperative  pain  scores,
t
p
t
(otal  opioid  consumption  and  side  effects  after  percuta-
eous nephrolithotomy.8--11
Pregabalin  is  a  structural  analog  of  the  inhibitory  neu-
otransmitter gaba-aminobutyric  acid,  with  anticonvulsant,
nti-hyperalgesic, and  anxiolytic  properties  like  gabapentin,
ut with  a  more  favorable  pharmacokinetic  proﬁle.12,13
t  was  proven  to  be  valuable  in  different  postoperative
ain situations,  including  dental  and  spinal  surgery,  laparo-
copic hysterectomy,  and  cholecystectomy  with  different
osage regimens,  besides  the  success  in  neuropathic  pain
anagement.14--19
We  hypothesized  that  adding  pregabalin  to  the  anal-
esic regimen  would  have  an  effect  on  postoperative  pain
cores and  renal  functions  and  reduce  opioid  consumption.
o the  best  of  our  knowledge  this  is  the  ﬁrst  study  designed
o evaluate  the  effect  of  single  dose  preoperative  75  mg
regabalin on  postoperative  pain  scores,  analgesic  consump-
ion and  renal  functions  expressed  by  creatinine  clearance
CrCl) and  blood  neutrophil  gelatinase-associated  lipocalin
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ﬁrst 12  patients  to  detect  a  signiﬁcant  difference  in  mor-
phine consumption  revealed  mean  morphine  consumption
as 1.6  ±  0.61  mg  vs.  1.2  ±  0.58  mg  in  control  and  pregabalinPregabalin  reduces  pain  and  opioid  consumption  after  PCNL
(NGAL)  and  cystatin  C  (Cys  C)  levels  in  patients  undergoing
PCNL.
Materials and  methods
Patient  selection
This  prospective,  randomized,  study  was  started  after
Institutional Ethics  Committee  approval  (Harran  University
Medical Faculty  Ethics  committee  no:  12-01-24)  and  after
obtaining written  informed  consent  from  all  patients.  The
study was  conducted  according  to  the  most  recent  version
of the  Declaration  of  Helsinki.  60  patients  between  the  ages
of 18  and  60  years  with  ASA  I-II  physical  status  who  under-
went elective  PCNL  under  general  anesthesia  were  enrolled
in the  study.  Patients  were  randomized  to  pregabalin  75  mg
and a  control  group  with  a  sealed  envelope  technique.  Pre-
gabalin was  given  orally,  1  h  prior  to  surgery  by  a  staff  nurse
who was  not  included  in  the  study  (Fig.  1).  Anaesthesiolo-
gists, surgeons  and  biochemists  were  blinded  to  the  groups.
A physician,  who  was  not  a  member  of  the  anesthesia  or
surgical team,  recorded  the  study  data.
Exclusion  criteria
Patients  with  a  history  of  drug  or  alcohol  abuse  and  patients
with chronic  pain  or  daily  intake  of  analgesics,  uncontrolled
diabetes mellitus  and/or  hypertension,  atherosclerotic
heart disease,  seizures,  impaired  kidney  or  liver  functions,
body mass  index  ≥35  kg/m2,  and  whom  could  not  control
a patient-controlled  analgesia  (PCA)  device  were  excluded
from the  study.
Anesthetic  management  and  operation
Standard  monitoring  comprised  of  non-invasive  arterial
pressure, electrocardiography,  and  pulse  oximetry  was  per-
formed. A  Bispectral  Index  (BIS)  A  2000  monitor  (Aspect
Medical Systems,  Natick,  MA,  USA)  was  also  employed
and baseline  values  for  all  variables  were  obtained.  The
values of  MAP,  HR  and  SpO2 were  recorded  at  baseline,
5, 10,  15,  20,  25,  30,  60  and  120  min  during  the  oper-
ation. The  anesthesia  technique  was  uniform  in  all  the
groups. Patients  were  induced  with  remifentanil  1  g  kg−1
and  propofol  2  mg  kg−1;  orotracheal  intubation  was  facili-
tated by  rocuronium  0.6  mg  kg−1.  Anesthesia  was  maintained
with 2--3%  sevoﬂurane,  50%  nitrous  oxide  in  oxygen  and
with 0.15  g  kg−1 min−1 remifentanil  infusion.  A  target  BIS
range of  40--55  was  used  to  guide  sevoﬂurane  administra-
tion.
Patient  controlled  analgesia  and  pain  scores
At  the  end  of  surgery,  residual  neuromuscular  paralysis  was
antagonized with  neostigmine  0.04  mg  kg−1 and  atropine
0.02 mg  kg−1.  The  patients  were  connected  to  a  morphine
patient controlled  analgesia  (PCA)  pump  on  arrival  at  the
PACU. The  PCA  pump  was  set  to  deliver  a  loading  dose  of
2.5 mg  and  an  incremental  dose  of  2.5  mg  at  a  lockout  inter-
val of  eight  minutes  and  a  four-hour  limit  of  50  mg.  The
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ncremental  dose  was  increased  to  3  mg,  the  lockout  interval
ecreased to  six  minutes  and  the  four-hour  limit  increased
o 60  mg,  whenever  the  analgesia  was  inadequate  after  one
our. Before  the  operation,  the  patients  were  trained  on
ow to  use  the  PCA  pump.
They  were  also  taught  how  to  express  the  level  of  pain
hey experienced  using  an  11-point  Visual  Analog  Scale
VAS), with  0 indicating  no  pain  and  10  indicating  the  worst
robable pain.  Vital  signs,  pain  scores,  morphine  consump-
ion and  adverse  effects  such  as  nausea,  vomiting,  pruritus,
rinary retention,  somnolence,  dizziness,  vision  abnormal-
ties (double  or  blurred)  and  headache  were  recorded.
ntravenous tenoxicam  20  mg  was  used  as  a  rescue  anal-
esic.
lood  sampling
reoperative  and  post-operative  blood  samples  were  col-
ected for  measurements  of  Cys  C,  NGAL,  BUN,  creatinine
Cr), sodium  and  potassium  in  the  preoperative  period  in  the
perating room  and  in  the  postoperative  2nd  and  24th  hour.
rCl was  calculated  with  the  Cockroft--Gault  Formula.20
iochemical  analysis
erum  Cys  C  [ALX-850-292-KI01  Cys  C  (human)  Elisa  Kit,
ioVendor, Lorrrach,  Germany]  and  NGAL  (RD191102200R
uman Lipocalin-2/NGAL  Elisa  Kit,  BioVendor  trademark,
eidelberg, Germany)  levels  were  analyzed  using  ELISA
its.
tatistical  analysis  and  study  sample  size
alculation
tatistical  analysis  was  performed  using  SPSS  for  Win-
ows, version  11.5  (SPSS,  Chicago,  IL,  USA).  Distribution
f continuous  variables  was  analyzed  with  the  one-sample
olmogorov--Smirnov test,  and  all  data  were  distributed
ormally. Comparisons  among  groups  with  respect  to  demo-
raphic data  were  evaluated  using  Chi-square;  pain  scores,
orphine consumption  and  biochemical  values  were  evalu-
ted using  independent  t-tests.  Repeated-measures  ANOVA
ith Bonferroni  post  hoc  test  was  used  to  compare  base-
ine and  follow-up  HR  and  MAP  measurements  in  each
roup and  independent  sample  t-test  was  used  to  com-
are these  hemodynamics  between  groups  in  different  time
ntervals. The  results  were  expressed  as  mean  and  SD  or
edian and  range  where  appropriate.  A  two  tailed  p-value
ess than  0.05  was  considered  to  be  statistically  signiﬁ-
ant.
Power calculations  based  on  a  pilot  study  with  theroups, respectively.  From  these  differences  and  assuming  a
wo tailed  ˛  value  of  0.05  (sensitivity  95%)  and  a  ˇ  value  0.20
study power:  80%),  we  determined  that  at  least  30  patients
ere required  in  each  group.
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68 patients screened for eligibility 
Excluded  (n = 4) 
♦ Patients not eligible: (n = 3) 
♦ Patients refused: (n = 1) 
Analyzed  (n = 30)
Protocol violation
(n = 2)  
Placebo (n = 32)
♦ Received allocated intervention (n = 32)   
Protocol violation
(n = 2)  
           Pregabalin 75 mg (n = 32)
♦ Received allocated intervention (n = 32)  
Analyzed  (n = 30) 
Allocation
Analysis
Follow - Up
Randomized (n = 64) 
Enrollment 
Figure  1  Flow  diagr
Results
A  total  of  68  patients  were  assessed  for  eligibility  and  four
cases were  excluded.  Of  the  64  subjects  receiving  medica-
tion after  randomization,  60  subjects  completed  the  study
(2 patients  in  each  group  were  excluded  due  to  protocol
violation). Of  the  60  patients  who  completed  the  study,  30
received pregabalin  (Fig.  1).
There  were  no  statistically  signiﬁcant  differences
between the  groups  regarding  age,  sex,  body  mass  index,
operation time,  and  intraoperative  remifentanil  consump-
tion (Table  1).
Postoperative  VAS  scores  of  patients  were  signiﬁcantly
decreased in  the  pregabalin  group  at  the  postoperative
30th min,  1st,  and  2nd  hour  when  compared  with  the
Table  1  Demographic  and  clinical  data  for  each  group  and
intraoperative  dose  of  remifentanil.
Characteristics  Control  (n  =  30)  Pregabalin  75  mg
(n  =  30)
Mean  ±  SD Mean  ±  SD
Age  (years)  38.45  ±  13.51  39.2  ±  11.66
Height  (cm)  164  ±  7.51  167.85  ±  8.82
Weight  (kg)  68.55  ±  10.05  72  ±  10.37
Gender  (M/F)  16/14  18/12
ASA (I/II)  10/20  12/18
BMI (kg/m2)  25.39  ±  2.34  25.45  ±  2.08
Intraoperative
remifentanil  (g)
1172 ±  332  1196  ±  334
Operation  time
(min)
115.25 ±  32.99  109.9  ±  22.27
p > 0.05 for all comparisons.
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ontrol  group  (p  =  0.002,  p  =  0.001  and  p  =  0.027,  respec-
ively, Table  2).  However,  there  were  no  statistically
igniﬁcant differences  between  postoperative  VAS  values  at
he 6th,  12th,  and  24th  hours,  between  groups  (p  >  0.05,  for
ll comparisons,  Table  2).
Postoperative  mean  morphine  consumption  was  sta-
istically signiﬁcantly  decreased  for  all  time  intervals
n the  pregabalin  group  compared  to  the  control  group
p =  0.002,  p  =  0.001,  p  =  0.001,  p  =  0.001,  p  <  0.001,  respec-
ively, Table  3).  None  of  the  patients  need  tenoxicam  as
escue analgesic.
The hemodynamic  data,  including  MAP,  HR,  and  SpO2,
ere not  different  between  the  groups  at  any  time  point
p >  0.05  in  all  time  intervals).
The  most  frequent  adverse  effects  were  PONV,  pruritus
nd urinary  retention  during  the  ﬁrst  24  h  after  surgery.  Inci-
ence of  PONV,  pruritus  and  urinary  retention,  dizziness,
ision abnormalities,  and  headache  were  similar  among  the
roups (p  >  0.05;  for  all  comparisons,  Table  4).  No  other
dverse effects,  such  as  respiratory  depression  and  somno-
ence, were  recorded  in  any  patient  from  either  group.
No  statistically  signiﬁcant  differences  were  found
etween the  two  groups  with  regard  to  renal  function,  CrCl,
r Cys  C  at  preoperative  and  postoperative  2nd  and  24th
our. Postoperative  NGAL  levels  in  the  pregabalin  group
ere not  signiﬁcantly  different  in  preoperative  and  post-
perative 2nd  hour  whereas  postoperative  24th  hour  NGAL
evels were  signiﬁcantly  decreased  in  the  pregabalin  group
p =  0.027,  Table  5).iscussion
ith  the  present  study,  we  have  tested  the  hypothe-
is that  single  dose  75  mg  pregabalin  administered  1  h
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Table  2  Mean  Visual  Analog  Scale  pain  scores.
Pain  intensity  VAS  Control  (n  =  30)  Pregabalin  75  mg  (n  =  30)  p
30  min  5.65  ±  0.67  4.95  ±  0.6  0.002a
1  h  3.85  ±  1.18  2.95  ±  0.39  0.001a
2  h  2.4  ±  0.94  1.85  ±  0.81  0.027a
6  h  1.25  ±  0.71  1.25  ±  0.85  0.616
12  h  0.9  ±  0.3  1.05  ±  0.75  0.671
24  h  0.8  ±  0.41  1  ±  0.79  0.484
VAS, Visual Analog Scale.
Values  are means ± SD.
a p 0.05 when comparing with the control group.
Table  3  Mean  morphine  consumption  of  groups  (mg).
Hour  Control  (n  =  30)  Pregabalin  75  mg  (n  =  30)  p
1  h 1.8  ±  0.62 1.2  ±  0.57 0.002a
2  h 3.5  ±  0.90 2.5  ±  0.94 0.001a
6  h  7.02  ±  2.5  4.55  ±  1.42  0.001a
12  h  9.6  ±  4  6.02  ±  2.56  0.001a
24  h  12.1  ±  5.4  7.07  ±  2.7  <0.001a
Values are means ± SD.
a p < 0.05.
Table  4  Side  effects  among  groups.
Side  effect  Control  (n  =  30)  Pregabalin  75  mg  (n  =  30)  Chi-square  p
Nausea  and  vomiting  (n)  3  (10%)  1  (3%)  NS
Pruritus  (n)  2  (6.6%)  0  NS
Urinary  retention  (n)  2  (6.6%)  0  NS
Respiratory  depression  (n)  0  0  NS
Somnolance  (n)  0  0  NS
Dizziness  (n)  0  1  (3%)  NS
Vision  abnormalities  (n)  0  1  (3%)  NS
Headache  (n)  0  1  (3%)  NS
Side effects among groups were evaluated using the Chi-square test.
NS,  not signiﬁcant.
Table  5  Laboratory  evaluation  among  groups  of  patients.
Control  (n  =  30)  Pregabalin  75  mg  (n  =  30)  p
NGAL  (ng/mL)
Baseline  172.2  ±  51.1  188.8  ±  43.6  0.23
2  h  188.9  ±  47  142.4  ±  76.6  0.58
24  h  200.4  ±  48.7  171  ±  55.2  0.027a
Cystatin  C  (ng/mL)
Baseline 1061.9  ±  48.5  1071.2  ±  59.7  0.89
2  h  1045.5  ±  292.3  1043.4  ±  184.1  0.76
24  h  1104.4  ±  79.7  1093  ±  97.4  0.6
CrCl  (mL/min)
Baseline  95.3  ±  4.1  95  ±  6.8  0.60
2  h  92.8  ±  3.4  93.4  ±  6.4  0.30
24  h  91.9  ±  4.3  
Values are means ± SD.
a p < 0.05 when comparing with the control group.92.75  ±  5.7  0.28
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reoperatively  would  have  effect(s)  on  postoperative
ain scores,  morphine  consumption,  renal  function,  and
emodynamic parameters  in  patients  undergoing  PCNL.  We
ave  shown  that  (1)  VAS  scores  were  statistically  decreased
n the  ﬁrst  2  postoperative  hours  in  the  pregabalin  group,
2) morphine  consumption  was  signiﬁcantly  decreased  at
ostoperative 24  h  in  all  time  intervals  in  the  pregabalin
roup, (3)  postoperative  24th  hour  NGAL  levels  were  also
igniﬁcantly decreased  in  the  pregabalin  group  (4)  and  both
roups have  similar  hemodynamic  effects,  with  a  similar
ide effect  proﬁle.
Several  techniques  have  been  reported  to  provide
ostoperative analgesia  for  percutaneous  nephrolithotomy,
ncluding paravertebral,  spinal  and  epidural  block,  local
nalgesic inﬁltration,  and  systemic  analgesic  therapy  modal-
ties, such  as  nonsteroidal  analgesic  drugs  and  opioids.21--25
here  has  been  no  study  focusing  on  preemptive  single  dose
regabalin administration  in  PCNL.
The  use  of  pregabalin  in  acute  postoperative  pain  has
een assessed  in  recent  studies.  A  meta-analysis  focusing
n perioperative  pregabalin  in  the  management  of  acute
ostoperative pain  revealed  decreased  opioid  consumption
nd opioid-related  adverse  effects  after  surgery;  however,
ostoperative pain  intensity  was  not  found  to  be  decreased
y pregabalin.26 In  another  meta-analysis,  administration
f pregabalin  during  a  short  perioperative  period  provides
dditional analgesia  in  the  short  term  but  at  the  cost  of
dditional adverse  effects,  and  they  reported  the  lowest
ffective dose  as  225--300  mg/d.27
Numerous  studies  on  the  efﬁcacy  of  pregabalin  for  post-
perative pain  have  revealed  contradictory  results,  probably
ue to  differences  in  dosage,  dosing  regimen,  or  the  char-
cteristics of  the  surgical  procedures.26,28--33 There  were
nly three  studies  that  emphasized  preoperative  single
ose 75  mg  oral  pregabalin  as  being  effective  in  decreasing
ostoperative pain  scores  in  different  clinical  settings,  such
s septoplasty,  laparoscopic  cholecystectomy  and  mammo-
lasty, whereas  50  mg  was  shown  not  to  be  effective  in  pain
ontrol in  laparoscopic  cholecystectomy.  In  this  study,  we
ried to  administer  the  lowest  dose  that  has  been  proven  to
e effective  in  a  postoperative  pain  setting,  so  we  used  a
reoperative single  dose  75  mg  pregabalin  in  PCNL.  In  this
tudy, we  were  able  to  demonstrate  superior  analgesia  with
5 mg  of  pregabalin  over  control  in  the  early  postoperative
eriod (ﬁrst  two  hours)  without  an  increase  in  side-effects
fter PCNL.  At  the  6th,  12th,  and  24th  hour,  no  differences
ere observed  in  VAS  levels.
Preemptive  pregabalin  administration  has  also  been
hown to  decrease  opioid  consumption  in  several  post-
perative settings  (mammoplasty,  hysterectomy,  lum-
ar spinal  fusion  surgery,  gynecological  laparoscopic
urgery, laparoscopic  sleeve  gastrectomy,  laparoscopic
holecystectomy).17--19,31,32,34 We  also  found  morphine  con-
umption to  be  decreased  for  all  time  intervals  during  the
ostoperative 24  h.  Increased  morphine  consumption  in  the
ontrol group  might  be  the  reason  for  similar  VAS  scores  after
he ﬁrst  two  hours  of  the  postoperative  period.
In  a  clinical  setting  with  PCNL  patients,  postopera-
ive renal  functions  might  also  be  in  the  consideration
f clinicians.  The  surgery  itself,  underlying  disease,  and
edications in  the  preoperative  and  postoperative  period
ight all  alter  renal  functions.  In  this  study,  our  secondaryH.  Aydog˘an  et  al.
utcomes  were  to  compare  CrCl  and  blood  NGAL  and  Cys
 levels  in  pre-  and  postoperative  periods  in  the  groups  to
ssess renal  functions.  Cys  C,  which  is  a  13-kD  cysteine  pro-
einase inhibitor  protein,  was  shown  to  predict  acute  kidney
njury (AKI)  earlier  than  other  biomarkers35 whereas  N-GAL
as shown  to  be  one  of  the  most  promising  biomarkers  of
idney injury,  which  could  predict  AKI  24--72  h before  a  diag-
ostic creatinine  increment.36--40 Patients  with  increased
erum NGAL  and  Cys  C  are  at  greater  risk  of  adverse  out-
omes both  in  the  presence  or  absence  of  an  increase  in
erum creatinine.41 In  this  study  CrCl  and  serum  Cys  C  lev-
ls were  similar  in  the  two  groups  in  all  measurements,
s well  as  postoperative  NGAL  levels  at  preoperative  and
ostoperative 2nd  hour.  However,  NGAL  was  signiﬁcantly
ecreased at  the  24th  hour  in  the  study  group  compared
o the  control  group.  These  results  indicate  that  pregabalin
id not  have  a  considerable  harmful  effect  on  renal  func-
ion, either  clinically  or  biochemically,  especially  in  this
linical setting.  Preemptive  pregabalin  was  also  shown  to
igniﬁcantly alter  hemodynamic  data  during  operations  in
ifferent clinical  settings.42,43 In  this  study  the  MAP  and
R were  also  similar  between  groups  for  any  time  inter-
al.
The common  adverse  effects  of  pregabalin  are  dose-
ependent drowsiness  and  dizziness16,33 and  the  possible
dvantages of  pregabalin  may  be  mitigated  by  these  trou-
lesome side-effects;  thus,  it  is  crucial  to  determine  the
owest optimal  dose  of  pregabalin  for  analgesic  use  without
he adverse  outcomes.  We  did  not  observe  any  signiﬁcant
ncrease in  side  effects,  including  PONV,  sedation,  dizziness,
eadache, visual  disturbance,  pruritus,  urinary  retention,
espiratory depression,  somnolence,  dizziness  and  vision
bnormalities during  the  ﬁrst  24  h  after  surgery  in  the  pre-
abalin group  compared  to  the  control  group.  This  might
e attributed  to  the  single  low  dose  of  pregabalin  in  this
tudy.
Several limitations  of  the  present  study  should  be  noted.
he potential  limitations  are  the  absence  of  a  placebo  group
nd the  absence  of  long-term  clinical  follow-up.  Further-
ore, the  majority  of  our  pregabalin  and  control  group
atients were  in  the  middle  age  group.  Different  results
ight be  obtained  with  children  or  a  geriatric  population
ue to  possible  altered  pharmacodynamics  and  pharmacoki-
etics of  pregabalin.
In conclusion,  oral  single-dose  preemptive  75  mg  prega-
alin was  effective  in  reducing  postoperative  pain  scores
nd total  analgesic  consumption  in  patients  undergoing
CNL without  leading  to  hemodynamic  instability  and  side
ffects.
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